coronavirus blockchain

This post is also available in: Español

In past posts, we have discussed how blockchain technology is revolutionizing increasingly diverse sectors (including luxury, art, and production chains). Unsurprisingly, in the context of the global crisis caused by the COVID-19 pandemic, blockchain technology has also been applied in the field of health, in the hope of reaching a turning point in the fight against the spread of the virus.

The World Health Organization, in cooperation with technology giants such as  IBM, enterprise blockchain platform Hacera, Oracle and Microsoft (along with other institutions that have joined the project), has launched a platform—configured as a blockchain-based coronavirus data center—to strengthen and ensure global information and proper monitoring of the pandemic.

As explained by Jonathan Levi (CEO of Hacera), the platform—called MiPasa and based on IBM’s blockchain technology Hyperledger Fabric—arises from the feeling that competent authorities lack the necessary information and knowledge to make appropriate decisions. MiPasa seeks to enable “early detection of COVID-19 carriers and infection hotspots” thanks to the exchange of (private) information between society, national authorities and health institutions. Despite the inputs and exchange of information feeding into it, MiPasa ensures patient privacy, as explained on its own website.  

The platform is based on analysis tools, and reliable and quality data sources. Thanks to these, MiPasa will enable individuals to check whether they have been in contact with another person that has tested positive for COVID-19 (by issuing an alert). MiPasa will also provide the competent authorities (e.g., scientific and health) with accurate data to enable them to detect critical infection hotspots and develop solutions to control and stop the spread of infections.

According to different sources, MiPasa is expected to incorporate new tools, including tools for data analysis and verification. Thus, blockchain technology could also play an essential role in this area, enabling the detection of COVID-19 infection sources (including the detection of potential asymptomatic carriers), as well as prompt and informed decision-making. In addition, this would not violate data privacy, which is a real challenge for modern clinical research.

Author: Ana Sánchez

This post is also available in: Español

Autores:

Asociada

47 artículos



ana.sanchezrodriguez@cuatrecasas.com